UY25050A1 - Metodo de tratamiento para diabetes mellitus - Google Patents
Metodo de tratamiento para diabetes mellitusInfo
- Publication number
- UY25050A1 UY25050A1 UY25050A UY25050A UY25050A1 UY 25050 A1 UY25050 A1 UY 25050A1 UY 25050 A UY25050 A UY 25050A UY 25050 A UY25050 A UY 25050A UY 25050 A1 UY25050 A1 UY 25050A1
- Authority
- UY
- Uruguay
- Prior art keywords
- diabetes mellitus
- treatment
- compound
- insulin
- mammal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 230000002641 glycemic effect Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25050A1 true UY25050A1 (es) | 2000-09-29 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25050A UY25050A1 (es) | 1997-06-18 | 1998-06-18 | Metodo de tratamiento para diabetes mellitus |
Country Status (30)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| PT1173434E (pt) | 1999-04-23 | 2003-12-31 | Smithkline Beecham Plc | Novo produto farmaceutico |
| SI1133312T1 (sl) * | 1999-06-21 | 2008-02-29 | Lilly Co Eli | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
| AU5760900A (en) * | 1999-06-25 | 2001-01-31 | Minimed, Inc. | Multiple agent diabetes therapy |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU2002248464A1 (en) | 2001-02-21 | 2002-09-12 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| WO2002100396A1 (en) * | 2001-06-07 | 2002-12-19 | Wyeth | COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| JP4551222B2 (ja) * | 2002-11-08 | 2010-09-22 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐｐａｒアゴニストとしての置換４−アルコキシオキサゾール誘導体 |
| US7264813B2 (en) * | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0719140B1 (en) * | 1993-09-15 | 2007-10-31 | Daiichi Sankyo Company, Limited | Use of thiazolidinediones to prevent or delay onset of niddm |
| IL122191A0 (en) * | 1995-08-10 | 1998-04-05 | Warner Lambert Co | Pharmaceutical compositions containing substituted benzopyrans |
| ATE259227T1 (de) * | 1995-09-18 | 2004-02-15 | Ligand Pharm Inc | Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Ceased
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
-
1999
- 1999-12-17 NO NO996265A patent/NO996265D0/no not_active Application Discontinuation
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25050A1 (es) | Metodo de tratamiento para diabetes mellitus | |
| UY25049A1 (es) | Composiciones para tratamiento para diabetes mellitus | |
| Idris et al. | Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug | |
| EA200601145A1 (ru) | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов | |
| AR057970A2 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones | |
| NO314065B1 (no) | Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes | |
| CY1117668T1 (el) | Φαρμακευτικες συστασεις περιλαμβανουσες ινσουλινη συμπλοκοποιημενη με μια δικετοπιπεραζινη | |
| RU98117673A (ru) | Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа | |
| BR0014142A (pt) | Composição de vacina e método de empregar a mesma | |
| BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
| WO2003075950A1 (en) | Minimising body weight gain in insulin treatment | |
| CY1105254T1 (el) | Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| AR008198A1 (es) | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona | |
| DE58906232D1 (de) | Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe. | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| UY25048A1 (es) | Composiciones para el tratamiento de la diabetes mellitus | |
| UY25051A1 (es) | Composiciones para el tratamiento de diabetes mellitus | |
| BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase | |
| PE20001239A1 (es) | Composicion de un sensibilizador de insulina | |
| BR0111536A (pt) | Sal de tiazolidinediona para tratamento de diabetes mellitus | |
| BR0112982A (pt) | Sal tartarato de derivado de tiazolidinadiona | |
| BR0112984A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
| BR0114364A (pt) | Derivado de tiazolidinediona e seu uso como anti-diabético | |
| NZ524933A (en) | Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090526 |